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Background
A previous therapeutic vaccine pilot study based on autol-
ogous dendritic cells pulsed with autologous heat inacti-
vated viruses HIV-1 obtained by plasmapheresis, showed
a decrease in the plasma viral load in 4 of 12 chronically
HIV-1-infected patients [García et al., J Infect Dis. 2005;
191: 1680–1685]. This vaccination strategy required to
submit the infected patients to 2 structured treatment
interruptions (STI): the first to recover enough viruses to
be used as antigen, and the second to assess virological
responses after the immunization. We aimed to study the
viral variability evolution changes occurring during off
therapy period, before and after vaccination.
Methods
12 patients on HAART underwent a HAART interruption
(STOP1) to obtain the virus by plasmaphereses. Then,
HAART was reinitiated and thereafter they received 4
immunizations. Six weeks after the last immunization,
HAART was definitely interrupted (STOP2). 4 controls
were submitted to both HAART interruptions but did not
receive any vaccination.
Sequences corresponding to the envelope C2V5 region
were analyzed from plasma samples obtained at baseline,
STOP1 and STOP2. Frequency and complexity values
were manually calculated. Genetic distances were con-
ducted using MEGA software version 4 [Tamura et al., Mol
Biol Evol., 2007; 24: 1596–1599].
Results
A high complexity was observed in all patients. The diver-
gence rate between stops was higher than between base-
line and STOP1, and divergence rate between baseline
and STOP 2 was lower than between baseline and STOP1.
In the immunized patients, the viral complexity was lower
in STOP2 than in STOP1, and there was a trend to
decrease amino acid changes and diversity after this ther-
apeutic vaccination.
Conclusion
All patients showed a great variability in all studied popu-
lations. We suggest that viruses observed in STOP2 are
more related to the baseline than with the viruses found
in STOP1 in all patients. Immunized patients showed
lower viral complexity after the therapeutic vaccination.
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